Mainz BioMed NV (MYNZ) Actualités

Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets

BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Form F-1 - Registration statement for certain foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

BERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

BERKELEY, Calif. and MAINZ, Germany, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ...

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a...

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including...

Mainz Biomed Provides Half Year 2024 Corporate Update

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a...

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of...